- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00236171
Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test
June 7, 2010 updated by: Technische Universität Dresden
The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sachsen
-
Dresden, Sachsen, Germany, 0351
- Technische Universität Dresden
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients older than 18 Years
- Negative urine pregnancy test
- Written informed consent
- Good compliance
Exclusion Criteria:
- Patients less than 18 years
- Pregnant patients
- Patients with renal insufficiency, liver diseases
- Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
- Patients who used topical antipsoriatics within two weeks prior to study
- Immunosuppressed Patients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
sum score of psoriasis plaque tests on day 11
|
Secondary Outcome Measures
Outcome Measure |
---|
20-MHz-ultrasound and OCT on day 11
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gottfried Wozel, Professor, Technische Universität Dresden
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Primary Completion (Actual)
April 1, 2006
Study Completion (Actual)
June 1, 2010
Study Registration Dates
First Submitted
October 4, 2005
First Submitted That Met QC Criteria
October 10, 2005
First Posted (Estimate)
October 12, 2005
Study Record Updates
Last Update Posted (Estimate)
June 8, 2010
Last Update Submitted That Met QC Criteria
June 7, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ETAPSO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
Clinical Trials on Protopic, Advantan
-
BioCis Pharma LtdCompleted
-
Astellas Pharma China, Inc.CompletedModerate/Severe Atopic DermatitisChina
-
Pusan National University HospitalCompletedSeborrheic DermatitisKorea, Republic of
-
Centre Hospitalier Universitaire de NiceTerminatedPigmentation Disorders | VitiligoFrance
-
Astellas Pharma IncCompletedDermatitis, AtopicPoland, Czech Republic, Hungary
-
Assaf-Harofeh Medical CenterUnknownTopical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot StudyAllergic ConjunctivitisIsrael
-
University Hospital, BordeauxCompleted
-
University of AberdeenCompletedCrohn DiseaseUnited Kingdom
-
Astellas Pharma IncCompletedDermatitis, AtopicFrance, Germany, Spain, Belgium, Netherlands, Finland, Austria, United Kingdom, Italy, Czech Republic, Switzerland, Portugal, Denmark
-
Astellas Pharma IncCompleted